PhotoPharmics, an American Fork-based privately held, clinical-stage medical device company developing treatments for treating neurodegenerative disorders through the eyes, has appointed Dr. Karl Kieburtz as chief medical officer. He will oversee the company’s clinical strategy and activities, including direct supervision of scientific development, clinical operations, data science, and interactions with the FDA. Kieburtz has experience executing clinical trials for Parkinson’s disease programs across all stages of development. He is currently president of Clintrex Research Corp. His role as CMO is part of an ongoing collaboration between PhotoPharmics and Clintrex. He also continues as professor of neurology at the University of Rochester, where he was founding director of the Center for Health & Technology (CHeT).